BARICITINIB
| Brand name | OLUMIANT |
|---|---|
| Active ingredient | BARICITINIB |
| Strength | 1MG |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | October 2019 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11045474 | November 2032 | use U-3372 |
| 9089574 | November 2032 | use U-3372 |
| 8158616 | May 2032 | substance, product |
| 9737469 | November 2031 | use U-3500 |
| 11806555 | November 2031 | use U-3500 |
| 8420629 | March 2029 | use U-247 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.